• AAPL 174.79
  • TSLA 244.88
  • AMZN 129.12
  • BTC-USD 26587.627
  • ETH-USD 1594.6216
  • EURUSD 1.0648
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. ABUS.US

Arbutus Biopharma Corp (ABUS NASDAQ) stock market data APIs

$1.97 0.04(2.1%) as of September 22, 2023

Arbutus Biopharma Corp Financial Data Overview

1.93
1.97
-
1.97
1.8815
1.86-3.145
323 M
168 M
23 535 K
-0.1
0
2.1328
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ABUS',
Type: 'Common Stock',
Name: 'Arbutus Biopharma Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000RR8V85',
ISIN: 'CA03879J1003',
CUSIP: '87911B209',
CIK: '1447028',
EmployerIdNumber: '98-0597776',
FiscalYearEnd: 'December',
IPODate: '2015-08-03',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
GicSector: 'Health Care',
GicGroup: 'Pharmaceuticals, Biotechnology & Life Sciences',
GicIndustry: 'Biotechnology',
GicSubIndustry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Arbutus Biopharma Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 23 535 K
  • EBITDA -73 384 000
  • Earnings Per Share -0.46
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Arbutus Biopharma Corp Earnings via APIs

  • Latest Release 2023-08-03
  • EPS/Forecast -0.11

Get Arbutus Biopharma Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Arbutus Biopharma Corp latest news via APIs

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 ...
  • ARBUTUS
  • ARBUTUS BIOPHARMA
  • ARBUTUS BIOPHARMA CORPORATION
  • NASDAQ:ABUS
  • PIPELINE UPDATES
  • PRODUCT / SERVICES ANNOUNCEMENT

Arbutus to Participate in Two Upcoming Investor Conferences

WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop no...
  • ARBUTUS
  • ARBUTUS BIOPHARMA
  • ARBUTUS BIOPHARMA CORPORATION
  • CALENDAR OF EVENTS
  • CONFERENCE CALLS/ WEBCASTS
  • INVESTOR CONFERENCES
  • NASDAQ:ABUS
  • WEBCAST
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com
We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy.